ArticleCancers2021
Efficacy and Safety of Carbon-Ion Radiotherapy for Stage I Non-Small Cell Lung Cancer with Coexisting Interstitial Lung Disease.
Article in Cancers, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Definitive radiotherapy for non-small-cell lung cancer: current practice and future directions.Japanese journal of radiology · 2026Review
- Carbon-Ion radiotherapy alone for inoperable locally advanced Non-Small cell lung cancer: A Japanese National registry study (J-CROS-LUNG).Japanese journal of radiology · 2026Observational
- AI-based prediction of recurrence after carbon ion radiotherapy for early stage non-small cell lung cancer.PloS one · 2026Article
- A narrative review of the early diagnosis and treatment of idiopathic pulmonary fibrosis with lung cancer.Journal of thoracic disease · 2025Review
- Clinical indications and future directions of carbon-ion radiotherapy: a narrative review.Ewha medical journal · 2024Review
- Safety and Efficacy of Single-Fraction Carbon-Ion Radiotherapy for Early-Stage Lung Cancer with Interstitial Pneumonia.Cancers · 2024Article
- Article
- Clinical results of carbon-ion radiotherapy for stage I non-small cell lung cancer with concomitant interstitial lung disease: a Japanese national registry study (J-CROS-LUNG).Journal of radiation research · 2023Article
- Basic and translational research on carbon-ion radiobiology.American journal of cancer research · 2023Review
- Value of carbon-ion radiotherapy for early stage non-small cell lung cancer.Clinical and translational radiation oncology · 2022Review
- Research Progress of Heavy Ion Radiotherapy for Non-Small-Cell Lung Cancer.International journal of molecular sciences · 2022Review
- Radiation-triggered acute exacerbation of progressive fibrotic interstitial lung diseases: 'Are we advancing the frontier or crossing a dangerous line?'Therapeutic advances in respiratory diseaseReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Interstitial lung disease (ILD) is a risk factor both for the development and treatment failure of lung cancer. In this retrospective study, we analyzed the outcome of carbon-ion radiotherapy (CIRT) in 124 patients with clinical stage I non-small cell lung cancer (NSCLC), of whom 26 (21%) had radiological signs of pre-existing ILD. ILD was diagnosed retrospectively by a pulmonologist based on critical review of CT-scans. Ninety-eight patients were assigned to the non-ILD group and 26 patients (21.0%) to the ILD group. There were significant differences in pre-treatment KL-6 values between the two groups. The three year overall survival and cause-specific survival rates were 83.2% and 90.7%, respectively, in the non-ILD group, and 59.7% and 59.7%, respectively, in the ILD group (between-group differences,
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.